Information  X 
Enter a valid email address

IXICO plc (IXI)

  Print      Mail a friend

Friday 17 January, 2020

IXICO plc

Result of AGM

RNS Number : 2251A
IXICO plc
17 January 2020
 

17 January 2020

 

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, can announce that resolutions one to five were put forward to its Annual General Meeting held earlier today and were duly passed whilst resolution six was not duly passed. The votes cast at the meeting were as follows:

 

Resolution

Description

Total Votes For

% Votes

Total Votes Against

% Votes

Withheld

Votes cast as a % of ISC

1

Reports and Accounts

21,954,961

100.00%

200

0.00%

800

46.62

2

Re-election of Directors







2a

Re-election of Giulio Cerroni

21,955,461

100.00%

500

0.00%

0

46.62

2b

Re-election of Grant Nash

21,955,461

100.00%

500

0.00%

0

46.62

3

Re-appointment of Auditors

21,949,261

99.99%

1,700

0.01%

5,000

46.61

4

Allotment of Securities

21,953,961

99.99%

1,700

0.01%

300

46.62

5

Disapply Pre-Emption Provisions

21,953,761

99.99%

1,900

0.01%

300

46.62

6

Amendment of Rule 3 of the Long-Term Incentive Plan

10,641,004

48.48%

11,309,157

51.52%

5,800

46.61

 

Charles Spicer, Chairman of the Board of IXICO, commented:

 

"The board notes the results of the resolution to approve the amendment to the IXICO LTIP and, over the coming months, will engage with those major shareholders who did not support this resolution to understand their concerns."

 

For further information please contact:

 

IXICO plc

Giulio Cerroni, Chief Executive Officer

 

+44 (0) 20 3763 7499

Grant Nash, Chief Financial Officer

 


Cenkos Securities PLC (Nominated adviser and sole broker)

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

+44 (0) 20 7397 8900



Optimum Strategic Communications

Mary Clark, Supriya Mathur, Manel Mateus

[email protected]

+44 (0) 203 950 9144




 

 


About IXICO

 

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGKKOBNABKDBDD

a d v e r t i s e m e n t